

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sean B. Carroll *et al.*

Serial No.: 10/662,918

Group No.: 1644

Filed: 09/15/03

Examiner: Kim, Yunsoo

Entitled: **Clostridial Toxin Disease Therapy**

**APPEAL BRIEF REPLACEMENT PAGE  
TRANSMITTAL IN RESPONSE TO  
NOTICE OF NON-COMPLIANCE**

**ATTENTION: Board of Patent Appeals and Interferences**

Mail Stop - Appeals

Commissioner for Patents


P.O. Box 1450

Alexandria, VA 22313-1450

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Patent and Trademark Office, via EFS.

Dated: March 23, 2009


  
Traci E. Light

BPAI:

Applicants hereby submit replacement page 3 of the previously filed Appeal Brief to the Board of Appeals and Interferences, in response to the Notice of Non-Compliance mailed February 19, 2009. Applicants also submit a one-month extension of time and requisite fee.

Please charge any additional fees, including any fees necessary for extensions of time, or credit overpayment to Deposit Account No. 08-1290.

Dated: March 23, 2009

  
Peter G. Carroll

Reg. 32,837

Attorney for Appellant

Medlen & Carroll, LLP

101 Howard Street, Suite 350

San Francisco, CA 94105

781-828-9870

**I. REAL PARTY IN INTEREST**

The real party in interest is Ophidian Pharmaceuticals, Inc., 2800 South Fish Hatchery Road, Madison, WI 53711.

**II. RELATED APPEALS AND INTERFERENCES**

There are no related applications pending appeal.

**III. STATUS OF CLAIMS**

Claims 1, 3-13 and 15-21 are rejected and are currently appealed. Claims 2 and 14 have been canceled.

**IV. STATUS OF AMENDMENTS**

All amendments in the case have been entered.

**V. SUMMARY OF CLAIMED SUBJECT MATTER**

The first independent claim (Claim 1) recites a method for administering an antibody reactive with *Clostridium perfringens* (pg 6 ln 19), **comprising** providing a subject (pg 5 ln 27), and an orally administrable solution (pg 5 ln 26-27) comprising avian antibody reactive with *Clostridium perfringens*, and orally administering said solution to said subject (pg 5 ln 28). Dependent Claim 3 recites that said solution is in the form of a nutritional formula (pg 6, ln 22). Dependent Claim 4 recites that said nutritional formula comprises infant formula (pg 6, ln 22). Dependent Claim 5, recited that said subject is an animal (pg 5 ln 22). Dependent Claim 6 recites that said administering is prophylactic (pg 5 ln 30). Dependent Claim 7 recites that said administering is therapeutic (pg 5 ln 26).

The second independent claim (Claim 8) recites a method for administering an antibody reactive with *Clostridium perfringens* (pg 6 ln 19), **consisting essentially of** providing a subject (pg 5 ln 27), and an orally administrable solution (pg 5 ln 26-27) comprising avian antibody reactive with *Clostridium perfringens*, and orally administering said solution to said subject (pg 5 ln 28). Dependent Claim 9 recites wherein said solution is in the form of a nutritional formula (pg 6 ln 22). Dependent Claim 10 recites wherein said nutritional formula comprises infant formula (pg 6 ln 22).